nuclear receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-27 and is reviewed periodically as new material appears.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
According to the series mythology, an extraterrestrial lifeform, known in the series' mythology simply as the Colonists, were originally present on Earth in the early stages of human evolution. They highly resemble the well-known "grey aliens" in their mature form. In their immature stage, they are more yellowish-colored, tall, and very aggressive, possessing fangs, claws and scale-like texture of their skin. This immature form is a protective stage, able to viciously defend itself from birth. This outer skin is eventually shed when the alien develops into its mature form. The immature form resembles that of a reptilian extraterrestrial and is referred to as the "long-clawed" form. The aliens were forced to abandon the planet during the last ice age as their viral form is deactivated by extreme cold. Upon their departure, they left behind underground deposits of the black oil virus, in preparation for their return. The virus apparently contains the aliens' genetic blueprints, awaiting reconstitution when the master species returns to Earth. While away from Earth, the Colonists evidently sought out life throughout the universe in an effort to subdue other species and take over the universe. Purportedly, the Colonists planned on returning to Earth in the year 2012, as The Smoking Man (William B. Davis) later remarks to Fox Mulder (David Duchovny) that the ancient Mayans were so terrified that they stopped their calendar on the exact date of colonization: December 22, 2012.
=== Surgical removal === Epididymotomy is the placement of an incision into the epididymis and is sometimes considered a treatment option for acute suppurating epididymitis. Epididymectomy is the surgical removal of the epididymis, sometimes performed for post-vasectomy pain syndrome and for refractory cases of epididymitis. Epididymectomy is also performed for sterilization on some male animals of livestock species so they can be used to detect estrus in females ready for artificial insemination.
Phosphorylation is the addition of phosphate groups to proteins, which is the most frequent regulatory modification mechanism in our cells. This process takes place in prokaryotic and eukaryotic cells (in this type of cells, a third or a half of the proteins experience phosphorylation). Because of its frequency, phosphorylation has a lot of importance in regulatory pathways in cells. The addition of a phosphoryl group to an enzyme is catalysed by kinase enzymes, while the elimination of this group is catalysed by phosphatase enzymes. The frequency of phosphorylation as a regulatory mechanism is due to the ease of changing from phosphorylated form to dephosphorylated form. Phosphorylation or dephosphorylation make the enzyme be functional at the time when the cell needs the reaction to happen. The effects produced by the addition of phosphoryl groups that regulate the kinetics of a reaction can be divided in two groups:
==== Finance and monetary policy ==== In 2008 and 2009, Sanders voted against the Troubled Asset Relief Program (TARP), a program to purchase toxic banking assets and provide loans to banks that were in free-fall. On February 4, 2009, he sponsored an amendment to ensure that TARP funds would not displace US workers. The amendment passed and was added to the American Recovery and Reinvestment Act of 2009. Among his proposed financial reforms is auditing the Federal Reserve, which would reduce its independence in monetary policy deliberations; Federal Reserve officials say that "Audit the Fed" legislation would expose the Federal Reserve to undue political pressure from lawmakers who do not like its decisions.
Sources: en.wikipedia.org
== See also == Abzyme: Antibodies can act as enzymes if they are selected against transition state analogues. Abzymes have a low KM, meaning that they readily bind a target molecule, but have low Vmax values, indicating a slow reaction rate. Biomimetics Bioorthogonal chemistry Catalysis Density functional theory Directed evolution Enzyme Molecular machine Molecularly imprinted polymer Nanochemistry Supramolecular chemistry Zeolite
The four substrates of this enzyme are 6-hydroxynicotinic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are 2,5-dihydroxypyridine, oxidised NAD+, water, and carbon dioxide. It is a flavoprotein that uses flavin adenine dinucleotide as a cofactor.
== Theoretical, actual, and percent yields == The percent yield is a comparison between the actual yield—which is the weight of the intended product of a chemical reaction in a laboratory setting—and the theoretical yield—the measurement of pure intended isolated product, based on the chemical equation of a flawless chemical reaction, and is defined as,
Sources: en.wikipedia.org
Amarasate is a supplement developed to trigger the "Bitter Brake" satiety mechanism, whereby bitter foods targeted to the small intestine trigger the release of the same appetite suppressing gut hormones that are typically elevated after a meal. The Bitter Brake concept was developed based on a combination of historical data supporting the use of bitter foods as a means to suppress appetite, and the discovery of bitter taste receptors (TAS2Rs) in appetite regulating enteroendocrine cells of the gastrointestinal tract. In vitro and biopsy research had identified TAS2Rs throughout the gastrointestinal tract and over 900 plant compounds were tested, with amarasate found to be a potent TAS2R activator. The role of gastrointestinal taste receptors has been examined in animal and human trials and a 2021 meta-analysis determined that pre-meal treatment with bitter compounds reduced energy intake, concluding that "bitter stimuli are most potent to influence eating behaviour".
The share of the world's lead production by the Eastern Bloc increased from 10% to 30%, from 1950 to 1990, with the Soviet Union being the world's largest producer during the mid-1970s and the 1980s, and China starting major lead production in the late 20th century. Unlike the European communist countries, China was largely unindustrialized by the mid-20th century; in 2004, China surpassed Australia as the largest producer of lead. As was the case during European industrialization, lead has had a negative effect on health in China.
== History == Brucella canis was first discovered in the United States by Leland Carmichael in 1966, when the bacterium was identified in canine vaginal discharge and the tissues from mass abortions in beagles. B. canis was said to be a biovar of B. suis. With recent research, PCR assay data was able to contradict B. canis and B. suis. PCR data showed a complete difference between the two strains along with B. suis biovars unattained from B. canis DNA. PCR assays have been proven beneficial when differentiating between Brucella strains and vaccine strains. Investigations into the bacterium revealed that domestic dogs are primarily affected along with other canine species. B. canis causes reproductive issues in female dogs, usually in the form of late-term spontaneous abortions. While in males, epididymitis, orchitis, and infertility were observed due to the bacterium. During the 1970s and 1980s, B. canis was reported in North America, Europe, and Asia. The reports were mainly from commercial breeding kennels wherein the bacterium can easily spread. Increase in infections were also attributed to the growing adoption of dogs as pets. By the 2000s, molecular analysis revealed that B. canis is unique from other Brucella species, categorized as a naturally occurring rough species that needs an anti-rough lipopolysaccharide reagent for detection. B. canis has been recognized as a growing zoonotic risk worldwide, having the ability to infect humans. Laboratory exposure or contact with pet dogs that had aborted fetuses were the main sources of exposure to the bacterium.
=== Synthesis === Dezocine [(−)-13β-amino-5,6,7,8,9,10,11,12-octahydro-5α-methyl-5,11-methanobenzocyclodecen-31-ol, hydrobromide] is a pale white crystal powder. It has no apparent odor. The salt is soluble at 20 mg/ml, and a 2% solution has a pH of 4.6. The synthesis of dezocine begins with the condensation of 1-methyl-7-methoxy-2-tetralone with 1,5-dibromopentane through use of NaH or potassium tert-butoxide. This yields 1-(5-bromopentyl)-1-methyl-7-methoxy-2-tetralone, which is then cyclized with NaH to produce 5-methyl-3-methoxy-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzocyclodecen-13-one. The product is then treated with hydroxylamine hydrochloride, to yield an oxime. A reduction reaction in hydrogen gas produces an isomeric mixture, from which the final product is crystallized and cleaved with HBr.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.